Mouse Avatars: Innovative Approach Holds Promise For Personalizing Cancer Treatment

Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.

Cancer is the second most common cause of death in the US, accounting for one of every four deaths and nearly 1,600 deaths per day in 2014 according to the American Cancer Society. While there are a plethora of chemotherapeutic drugs available to treat cancer, the genetic and epigenetic variability between the tumors of cancer patients creates significant challenges in accurately predicting which individuals will respond to a specific drug. Despite ongoing efforts to use genomic sequencing to improve patient response to chemotherapy, the personalization of oncology drugs remains limited. Furthermore, 83% of the $1.3 billion cost to successfully bring one drug through the FDA is spent on failed clinical trials due to the inability to predict the likelihood that patients will respond to new treatments.

To improve the success of cancer treatment and clinical trials, Hackensack, NJ-based Champions Oncology Inc. has developed TumorGraft technology,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Finland Cracks Down On Software That Needs Regulating As A Medical Devices

 

Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it. 

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.